Gram positives focus on mrsa from bench to bedside
This presentation is the property of its rightful owner.
Sponsored Links
1 / 51

Gram-Positives: Focus on MRSA From Bench to Bedside PowerPoint PPT Presentation


  • 109 Views
  • Uploaded on
  • Presentation posted in: General

Gram-Positives: Focus on MRSA From Bench to Bedside . Andrew E. Simor, MD, FRCPC, FACP Sunnybrook Health Sciences Centre University of Toronto. Disclosures. I have received grants, or served as a consultant on Advisory Boards for: Astellas Pharma BD GeneOhm Janssen-Ortho

Download Presentation

Gram-Positives: Focus on MRSA From Bench to Bedside

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Gram positives focus on mrsa from bench to bedside

Gram-Positives: Focus on MRSA From Bench to Bedside

Andrew E. Simor, MD, FRCPC, FACP

Sunnybrook Health Sciences Centre

University of Toronto


Gram positives focus on mrsa from bench to bedside

Disclosures

  • I have received grants, or served as a consultant on Advisory Boards for:

    • Astellas Pharma

    • BD GeneOhm

    • Janssen-Ortho

    • Pfizer Canada

    • Sepracor Pharmaceuticals


Gram positives focus on mrsa from bench to bedside

Resistant Gram-Positive Pathogens

MRSA

VRE

C. difficile


Staphylococcus aureus

Staphylococcus aureus

  • S. aureus is most common cause of healthcare-associated infections

  • MRSA is the major antibiotic-resistant organism in hospitals; CA-MRSA increasing


Annual deaths in the u s for selected infectious diseases

Annual Deaths in the U.S. for Selected Infectious Diseases

DeLeo and Chambers JCI2009

adapted from Klevens JAMA2007

1.Boucher CID2008; 46(Suppl 5):S344-9

2. http://www.cdc.gov/hiv/topics/surveillance/basic.htm#ddaids

3 http://www.cdc.gov/TB/publications/factsheets/statistics/TBTrends.htm


Mrsa in canada 1995 2009

MRSA in Canada, 1995-2009

Simor, Infect Control Hosp Epidemiol 2010; Canadian Nosocomial Infection Surveillance Program


Gram positives focus on mrsa from bench to bedside

MRSA in Canadian Hospitals

Simor, Infect Control Hosp Epidemiol 2010


Gram positives focus on mrsa from bench to bedside

MRSA Infections, 2008-09 (30%)

%

Canadian Nosocomial Infection Surveillance Program


Mrsa in canadian hospitals

MRSA in Canadian Hospitals

  • CANWARD: 10 hospitals, 2008

  • MRSA accounted for 5% of all clinical isolates (5% blood, 6% respiratory, 12% wound isolates)

Zhanel, Antimicrob Agents Chemother 2010


Mrsa bloodstream infections

MRSABloodstream Infections

*Jeyaratnam, BMJ 2008; †QMPLS, 2009; §Institut National de Santé Publique du Québec, 2008; **Adam, Diagn Microbiol Infect Dis 2011


Mrsa in canadian hospitals 2010

MRSA in Canadian Hospitals, 2010

There were:

approx 36,000 new MRSA patients

11,000 new MRSA infections

2,200 MRSA-related deaths

$250 million excess costs attributable to MRSA


Gram positives focus on mrsa from bench to bedside

Molecular Epidemiology of CA-MRSA

Otter, Lancet ID, 2010


Mrsa in canada evolving molecular epidemiology

MRSA in Canada:Evolving Molecular Epidemiology

Simor, Infect Control Hosp Epidemiol 2010;

Simor, IDSA 2010


Gram positives focus on mrsa from bench to bedside

Canadian Nosocomial Infection Surveillance Program


Gram positives focus on mrsa from bench to bedside

Canadian Nosocomial Infection Surveillance Program


Ca mrsa epidemiology

CA-MRSA Epidemiology

  • neonates, children

  • homeless, incarcerated, IVDU

  • MSM, HIV-infected

  • military personnel

  • athletes (contact sports)

  • native aboriginals

  • household contacts

  • veterinarians, livestock handlers

David, Clin Microbiol Rev 2010


Livestock associated mrsa

Livestock-Associated MRSA

  • SCCmec IV, PVL-neg

  • Pigs: ST398 (not typeable by PFGE SmaI)(Voss, Emerg Infect Dis 2005; Khanna, Vet Microbiol 2008; Golding, Emerg Infect Dis 2010)

  • Horses: CMRSA-5 (USA500; t007) (Weese, Emerg Infect Dis 2005)


Mrsa in domestic pets

MRSA in Domestic Pets

  • reported in cats, dogs, guinea pigs, parrots

  • a variety of clones, often HA-MRSA

    (Weese, Vet Microbiol 2006;

    David, Clin Microbiol Rev 2010)


Ca mrsa as a cause of healthcare associated infections

CA-MRSA as a Cause of Healthcare-Associated Infections

  • USA400 post-partum infections, NY mastitis, cellulitis, abscesses(Saiman, CID 2003)

  • USA300 prosthetic joint infections, SSIs (Kourbatova, Am J Infect Control 2005; Patel, J Clin Microbiol 2007)

  • USA300 accounted for 28% healthcare-associated bacteremias, 20% nosocomomial MRSA BSIs, Atlanta, GA(Seybold, CID 2006)

  • USA300 transmission in a Canadian Burn unit(McGuire, SHEA 2007)


Ca mrsa in canadian hospitals

CA-MRSA in Canadian Hospitals

  • predominantly SSTI, in younger adults, Western Canada

  • 60% community-associated; 40% healthcare-associated

  • 94% PVL-positive (predominantly CMRSA-10; SCCmec type IV)

Simor, Infect Control Hosp Epidemiol 2010


Ca mrsa enhanced virulence

CA-MRSA: Enhanced Virulence?

  • associated with severe and recurrent SSTI, often in individuals without predisposing risk factors

  • associated with necrotizing pneumonia

  • appears to be easily transmitted in hospitals, households, and the community


Ca mrsa virulence

CA-MRSAVirulence

  • USA 300/400 more virulent than other strains of S. aureus/MRSA in a mouse model of bacteremia

  • more resistant to killing by human PMNs

Voyich, J Immunol 2005;

Li, PNAS 2009


Gram positives focus on mrsa from bench to bedside

MRSA USA300 Virulence Factors

David, Clin Microbiol Rev 2010


Ca mrsa virulence1

CA-MRSAVirulence

  • Panton-Valentine Leukocidin (PVL)

  • -hemolysin (increased expression in CA-MRSA; -hemolysin antibody protective in mouse model) (Wardenburg, Nature Med 2007)

  • Argenine catabolic mobile element (ACME;unique to CA-MRSA, S. epidermidis; may help strain evade host response and facilitate colonization) (Goering, J Clin Microbiol 2007)


Gram positives focus on mrsa from bench to bedside

PVL Gene and Survival

Gillet, Lancet 2002


Pvl gene and virulence

PVL Gene and Virulence

  • using isogenic PVL knockout mutants in murine models (subcut abscess, pneumonia) has given conflicting results (Voyich, J Infect Dis 2006; Labandeira-Rey, Science 2007)

  • PVL does appear to contribute to virulence in a rabbit bacteremia model (An Diep, PLoS ONE 2008)


Mrsa impact

MRSAImpact

  • attributable mortality and morbidity(Whitby, Med J Austr 2001; Cosgrove, Clin Infect Dis 2003)

  • prolonged hospital length of stay(Engemann, Clin Infect Dis 2003; Cosgrove, Infect Control Hosp Epidemiol 2005)

  • excess/attributable costs, $14,360(Kim, Infect Control Hosp Epidemiol 2001)


Impact of mrsa infections

Impact of MRSA Infections

* Cosgrove, Clin Infect Dis 2003; Melzer, Clin Infect Dis 2003; Wyllie, BMJ 2006

† Combes, AJRCCM 2004; DeRyke, Chest 2005; Zahar, Clin Infect Dis 2005


Why does antibiotic resistance affect outcome

Why does antibiotic resistance affect outcome?

  • Host factors

  • Organism virulence

  • Delay in instituting effective therapy (or vancomycin less effective)

Bradley, Clin Infect Dis 2002; Paterson, Clin Infect Dis 2004; Kim, Antimicrob Agents Chemother 2008


Mrsa bacteremia in canadian hospitals 2008 09

MRSA Bacteremia in Canadian Hospitals, 2008-09

  • MRSA bacteremia rates:0.50 per 1,000 admissions 0.61 per 10,000 patient-days

  • source of bacteremia:skin, soft tissue, SSI - 36% 1y bacteremia, CA-BSI- 24% pneumonia- 16%

  • healthcare-associated, 72% community-associated, 28%(CMRSA-2, 49%; CMRSA-10, 32%)

Simor, IDSA 2010


Mrsa bacteremia in canadian hospitals 2008

MRSA Bacteremia in Canadian Hospitals, 2008

  • 30-day all-cause mortality: 23%

  • variables associated with mortality: age > 65 yrs (OR 2.3, 95% CI 1.3-3.9) pneumonia (OR 4.0, 95% CI 2.0-7.8) HA-MRSA (OR 2.3, 95% CI 1.1-4.8)

  • mortality not associated with PFGE type, PVL gene, or reduced susceptibility to vancomycin (3 isolates with MIC = 2)

Simor, IDSA 2010


Mrsa infection

MRSA Infection

How does treatment affect outcome?


Vancomycin susceptibility breakpoints in staphylococci

Vancomycin SusceptibilityBreakpoints in Staphylococci

CLSI


Gram positives focus on mrsa from bench to bedside

Predictors of Persistent MRSA

Bacteremia (multivariate analysis)

Yoon, J Antimicrob Chemother 2010


Vancomycin mics and treatment outcome in mrsa bacteremia

Vancomycin MICs and Treatment Outcome in MRSA Bacteremia

p=0.003

p=0.01

1 Sakoulas, J Clin Microbiol 20042 Moise-Broder, Clin Infect Dis 2004


Mrsa pneumonia outcome

MRSA PneumoniaOutcome

  • 158 cases MRSA pneumonia (HAP/VAP)

  • 28-day mortality: 32%

  • mortality increased with vancomycin MIC > 1.5 µg/ml

Haque, Chest 2010


What about hvisa

What about hVISA?

  • hVISA (heteroresistant): MIC susceptible (< 4 µg/ml), but with a resistant sub-population; detected by PAP-AUC

  • preliminary step towards development of VISA (Hiramatsu, Lancet ID 2001)

  • may be associated with treatment failure (Sakoulas, Antimicrob Agents Chemother 2005)


Gram positives focus on mrsa from bench to bedside

Impact of hVISA: A Meta-Analysis

van Hal, Antimicrob Agents Chemother 2011


Gram positives focus on mrsa from bench to bedside

Canadian MRSA and Vancomycin

Adam, Antimicrob Agents Chemother 2010


Vancomycin and treatment failure

Vancomycin and Treatment Failure

  • higher vancomycin MICs associated with worse outcome

  • thus: recommendations to use higher vancomycin doses (target trough: 15-20 µg/ml) (Liu, Clin Infect Dis 2011)

  • but, higher troughs not associated with better outcome; associated with increased nephrotoxicity (Hidayat, Arch Intern Med 2006)


Gram positives focus on mrsa from bench to bedside

Liu, Clin Infect Dis 2011


Gram positives focus on mrsa from bench to bedside

MRSA Treatment

Guidelines:

Evidence-Based?

Liu, Clin Infect Dis 2011


Can we do a better job of preventing mrsa infection

Can we do a better job of preventing MRSA infection?


Mrsa infection control strategies

MRSA Infection Control Strategies

contact precautions

screening

decolonization


Evidence for effectiveness of active surveillance contact precautions

Evidence for Effectiveness of Active Surveillance + Contact Precautions

ecological studies (Verhoef, EJCMID 1999; Tiemersma, Emerg Infect Dis 2004)

observational/quasi-experimental studies (Jernigan, Am J Epidemiol 1996; Chaix, JAMA 1999; Huang, Clin Infect Dis 2006; Robicsek, Ann Intern Med 2008)

mathematical models (Bootsma, PNAS 2006)


Pcr vs chromogenic media

PCR vs. Chromogenic Media

  • prospective, cross-over study, 2 hospital wards, UK

  • median time to report MRSA: 47 hrs vs. 21 hrs (culture vs. PCR; p<0.001)

  • no reduction in MRSA transmission

Aldeyab, J Hosp Infect 2009


Mrsa decolonization

MRSA Decolonization

decolonization to prevent staphylococcal SSI (Bode, N Engl J Med 2010)

observational studies with mupirocin or other agents as part of infection control measures (Hill, J Antimicrob Chemother 1998; Strausbaugh, ICHE 1992; Sandri, ICHE 2006; Ridenour, ICHE 2007; Bowler, ICHE 2010)

interrupted time-series analysis in 2 UK ICUs: chlorhexidine gluconate baths reduced MRSA transmission, but emergence of strains with reduced susceptibility to CHG (Batra, Clin Infect Dis 2010)


Mrsa the dutch experience

MRSA:The Dutch Experience

national “search and destroy policy”

screening patients, staff

strict isolation

decolonization

environmental cleaning

outbreak control

Verhoef, EJCMID 1999; van Trijp, Infect Control Hosp Epidemiol 2007


Gram positives focus on mrsa from bench to bedside

MRSA Bacteremia - England

Pearson, J Antimicrob Chemother 2009


Mrsa in canada 2011

MRSA in Canada - 2011

  • Infectious morbidity of HA-MRSA and CA-MRSA continues to increase

  • Need to better understand variables associated with treatment failure

  • Need to better understand and implement effective strategies for MRSA infection prevention


The end

The End


  • Login